2019 Novel Coronavirus (2019-nCoV) 
Update # 3

Key Points and Recommendations:

1. There are now 8 confirmed infections of the 2019 novel coronavirus (2019-nCoV) in the United States, including in California (3), Illinois (2), Washington State (1), Arizona (1), and most recently Massachusetts (1). There are no confirmed infections in NH, and the two individuals previously undergoing testing are negative for the 2019-nCoV. There are no additional persons under investigation (PUI) in NH at this time.

2. Clinicians should review the recent U.S. Centers for Disease Control and Prevention (CDC) HAN for updated clinician guidance (see attached), including updated infection prevention and control guidance specific to 2019-nCoV.

3. Given the expansion of the 2019-nCoV outbreak to other parts of China, healthcare reception and providers should now ask patients presenting with a fever or respiratory illness about travel to anywhere in China or known close contact to a person confirmed to have 2019-nCoV infection in the 14 days before symptom onset.

4. All people should be advised to avoid travel to China.

5. The U.S. Department of Health and Human Services (HHS) is escalating the national response to slow the spread of this novel coronavirus in the U.S. as outlined below.

6. All asymptomatic travelers from China should be instructed to self-isolate for 14 days from their last day of travel to China, including avoiding public settings and any further travel. These individuals should also be instructed to self-monitor for symptoms and to contact the NH Division of Public Health Services (DPHS) at 603-271-4496 if they develop fever or respiratory illness within 14 days of travel to China.

7. Anybody who traveled to locations in Hubei Province, China within the last 14 days, even if asymptomatic, should be reported to NH DPHS for more active monitoring.

8. Any patients presenting with fever or respiratory illness within 14 days of travel to China should be reported immediately to the Bureau of Infectious Disease Control by calling 603-271-4496 (after hours 603-271-5300).

Situational Update:

In December 2019, an outbreak of a new coronavirus was detected in Wuhan City, China causing a cluster of viral pneumonias; the cause of the respiratory illnesses was identified to be a new 2019 novel coronavirus (2019-nCoV). Over the last several weeks, the outbreak has spread to other parts of China and internationally. As of February 1st, more than 12,000 infections with the 2019-nCoV have been identified globally in more than 25 different countries, including more than 250 deaths. While the vast majority of infections have been identified in mainland China, specifically Hubei Province, China (including Wuhan City), there have so far been eight infections identified in the United States, including in the states of California (3), Illinois (2), Washington State (1), Arizona (1), and most recently Massachusetts (1).
Given the acceleration of the outbreak and global spread, the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. On January 31, 2020, The U.S. Health and Human Services (HHS) Secretary Alex Azar declared that the 2019-nCoV presents a public health emergency in the United States and implemented the following measures that go into effect on Sunday 2/2/2020 at 5:00pm Eastern Standard Time:

- Any U.S. citizen returning to the U.S. who has been in Hubei Province, China in the previous 14 days will be subject to up to 14 days of mandatory quarantine at a U.S. facility for health monitoring.
- Any U.S. citizens returning to the U.S. who have been to the rest of mainland China within the previous 14 days will undergo proactive entry screening at a select number of ports of entry [including the following 7 airports: New York (JFK), Atlanta (ATL), Chicago (ORD); Seattle (SEA); San Francisco (SFO), Los Angeles (LAX), and Honolulu (HNL)] and up to 14 days of monitored “self-quarantine” to ensure they have not contracted the virus and do not pose a public health risk.
- Any foreign national (other than immediate family of U.S. citizens and permanent residents of the U.S.) who have traveled in China in the prior 14 days will be denied entry in to the United States.

**White House Briefing on Coronavirus Response**

*January 31, 2020*


**Additional Information**

• For any questions regarding this notification, please call the NH DHHS, DPHS, Bureau of Infectious Disease Control at (603) 271-4496 during business hours (8:00 a.m. – 4:30 p.m.).

• If you are calling after hours or on the weekend, please call the New Hampshire Hospital switchboard at (603) 271-5300 and request the Public Health Professional on-call.

• To change your contact information in the NH Health Alert Network, contact Adnela Alic at (603) 271-7499 or email Adnela.Alic@dhhs.nh.gov.

Status: Actual
Message Type: Alert
Severity: Moderate
Sensitivity: Not Sensitive
Message Identifier: NH-HAN 20200201 nCoV-2019 Update #3
Delivery Time: 12 hours
Acknowledgement: No
Distribution Method:
Distributed to: Physicians, Physician Assistants, Practice Managers, Infection Control Practitioners, Infectious Disease Specialists, Community Health Centers, Hospital CEOs, Hospital Emergency Departments, Nurses, NHHA, Pharmacists, Laboratory Response Network, Manchester Health Department, Nashua Health Department, Public Health Networks, DHHS Outbreak Team, DPHS Investigation Team, DPHS Management Team, Northeast State Epidemiologists, Zoonotic Alert Team, Health Officers, Deputy Health Officers, MRC, NH Schools, EWIDS
From: Benjamin P. Chan, MD, MPH, State Epidemiologist
Originating Agency: NH Department of Health and Human Services, Division of Public Health Services

Attachments:
1. CDC HAN
2. CDC Flowchart to Identify and Assess 2019 Novel Coronavirus
Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV)

Summary
The Centers for Disease Control and Prevention (CDC) continues to closely monitor an outbreak of respiratory illness caused by a novel coronavirus (2019-nCoV) that was initially detected in Wuhan City, Hubei Province, China in December 2019.

This CDC Health Alert Network (HAN) Update provides a situational update and interim guidance to state and local health departments that supersedes guidance in CDC’s HAN 426 distributed on January 17, 2020. It also adds:

- and for public health officials on the evaluation and testing of patients under investigation (PUIs) for 2019-nCoV (https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html), and

Early in the outbreak, many of the patients with respiratory illness caused by 2019-nCoV in China had exposure to a large seafood and live animal market, suggesting animal-to-human transmission. More recently, cases have been confirmed with no exposure to animal markets, indicating that person-to-person spread of the virus has occurred. Chinese officials report that sustained person-to-person spread in the community is occurring in China.

The first US case-patient was identified on January 21, 2020, and had recently traveled from Wuhan, China. Since that time, six additional cases have been confirmed in the United States, four among persons who traveled from Wuhan, and one a close contact of a confirmed case. Globally, reported illnesses in people with 2019-nCoV have ranged from mild (no or few signs and symptoms), to severe, including death. These findings are consistent with other coronaviruses, including Severe Acute Respiratory Syndrome (SARS) (https://www.cdc.gov/sars/) and Middle East Respiratory Syndrome (MERS) (https://www.cdc.gov/coronavirus/mers/index.html). Additional information about 2019-nCoV is needed to better understand transmission, disease severity, and risk to the general population. The goal of the ongoing US public health response is to identify and contain this outbreak and prevent sustained spread of 2019-nCoV in the United States.

Recommendations for Screening of Patients for 2019-nCoV in Healthcare Facilities
Recommendations for screening of patients for possible 2019-nCoV infection are based on (1) current knowledge of the characteristics of clinical illness observed in early cases, and (2) the geographic distribution of current cases. They reflect the current public health goal of rapidly containing and preventing transmission of 2019-nCoV illness.

Patients presenting to healthcare facilities should be assessed for exposures associated with risk of 2019-nCoV infections (e.g., travel to China or close contact with a confirmed case) and for symptoms consistent with 2019-nCoV infection (https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-
The assessment is intended to allow healthcare providers to make decisions about appropriate infection control and management of patients. Note that the signs and symptoms of 2019-nCoV overlap with those associated with other viral respiratory tract infections. Given the time of year, common respiratory illnesses, including influenza, should also be considered in patients who are screened. (Figure 1)

Clinicians should ask:

- Does the person have fever or symptoms of lower respiratory infection, such as cough or shortness of breath?

AND

- Has the patient traveled to mainland China within 14 days of symptom onset?

OR

- Has the patient had close contact\(^1\) with a person confirmed with 2019-nCoV infection?

*Documentation of laboratory confirmation of 2019-nCoV may not be possible for travelers or persons caring for patients in other countries. For more clarification on the definition of close contact see CDC's Interim Guidance for Healthcare Providers: [www.cdc.gov/coronavirus/2019-ncov/related/clinical-echocardiography.html](www.cdc.gov/interim-guidance-for-healthcare-providers)
If a patient meets these criteria:

- To minimize the risk that other people will be exposed to individuals who may have 2019-nCoV, patients who report having these symptoms should be asked to wear a surgical mask as soon as they are identified and directed to a separate area, if possible, with at least 6 feet (2 meters) separation from other persons. Patients should be evaluated in a private room with the door closed, ideally an airborne infection isolation room (AIIR), if available. Healthcare personnel entering the room should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield). For more information about this, see CDC’s Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (2019-nCoV) in a Healthcare Setting (https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html).

Clinicians should immediately notify the healthcare facility’s infection control personnel and local health department. The health department will determine if this patient needs to be considered a PUI for 2019-nCoV and be tested for infection.

**Criteria to Guide Evaluation and Testing of Patients Under Investigation (PUI) for 2019-nCoV**

Local health departments, in consultation with clinicians, should determine whether a patient is a PUI for 2019-nCoV. The CDC clinical criteria for 2019-nCoV PUIs have been developed based on available information about this novel virus, as well as what is known about SARS and MERS. These criteria are subject to change as additional information becomes available.

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>AND</th>
<th>Epidemiologic Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever² or signs/symptoms of lower respiratory illness (e.g. cough or shortness of breath)</td>
<td>AND</td>
<td>Any person, including health care workers, who has had close contact¹ with a laboratory-confirmed³ 2019-nCoV patient within 14 days of symptom onset</td>
</tr>
<tr>
<td>Fever² and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath)</td>
<td>AND</td>
<td>A history of travel from Hubei Province, China within 14 days of symptom onset</td>
</tr>
<tr>
<td>Fever² and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath) requiring hospitalization⁴</td>
<td>AND</td>
<td>A history of travel from mainland China within 14 days of symptom onset</td>
</tr>
</tbody>
</table>
These criteria are intended to serve as guidance for evaluation and testing. Patients should be evaluated and discussed with public health departments on a case-by-case basis for possible 2019-nCoV infection. Testing decisions might be further informed by the clinical presentation or exposure history (e.g., uncertain travel or exposure), and the presence of an alternative diagnosis that explains their clinical presentation.

**Recommendations for Reporting, Testing, and Specimen Collection**

Healthcare providers should immediately notify infection control personnel at their healthcare facility if a patient is classified a PUI for 2019-nCoV. State health departments that have identified a PUI should immediately contact CDC’s Emergency Operations Center (EOC) at 770-488-7100 and complete a 2019-nCoV PUI case investigation form ([https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html#reporting-testing-specimen-collection](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html#reporting-testing-specimen-collection)). CDC’s EOC will assist local and state health departments with obtaining, storing, and shipping appropriate specimens to CDC, including afterhours or on weekends or holidays. Currently, diagnostic testing for 2019-nCoV can be done only at CDC. Testing for other respiratory pathogens should not delay specimen shipping to CDC.

For initial diagnostic testing for 2019-nCoV, CDC recommends collecting and testing upper respiratory (nasopharyngeal AND oropharyngeal swabs), and lower respiratory (sputum, if possible)) for those patients with productive coughs. Induction of sputum is not indicated. Specimens should be collected as soon as possible once a PUI is identified, regardless of the time of symptom onset. See *Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV)* ([https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html)).

**Recommendations for Healthcare Providers**

No vaccine or specific treatment for 2019-nCoV infection is available. At present, medical care for patients with 2019-nCoV is supportive.

Persons with confirmed or suspected 2019-nCoV infection who are hospitalized should be evaluated and cared for in a private room with the door closed, ideally an airborne infection isolation room, if available. For more information, see *Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (2019-nCoV) in a Healthcare Setting* ([https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html](https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html)).


**Notes**

1 Close contact is defined as:
   a) being within approximately 6 feet (2 meters), or within the room or care area, of a 2019-nCoV case for a prolonged period of time while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection); close contact can include caring for, living with, visiting, or sharing a health care waiting area or room with a 2019-nCoV case - or -
   b) having direct contact with infectious secretions of a 2019-nCoV case (e.g., being coughed on) while not wearing recommended personal protective equipment.

2 Fever may be subjective or confirmed

Data to inform the definition of close contact are limited. Considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person with 2019-nCoV (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special consideration should be given to those exposed in healthcare settings.

3 Documentation of laboratory-confirmation of 2019-nCoV may not be possible for travelers or persons caring for patients in other countries.

4 Category also includes any member of a cluster of patients with severe acute lower respiratory illness (e.g., pneumonia, ARDS) of unknown etiology in which 2019-nCoV is being considered that requires hospitalization. Such persons should be evaluated in consultation with state and local health departments regardless of travel history.

**For More Information**


---

*The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.*

---

**Categories of Health Alert Network messages:**

- **Health Alert**: Requires immediate action or attention; highest level of importance
- **Health Advisory**: May not require immediate action; provides important information for a specific incident or situation
- **Health Update**: Unlikely to require immediate action; provides updated information regarding an incident or situation
- **HAN Info Service**: Does not require immediate action; provides general public health information

---

##This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, epidemiologists, HAN coordinators, and clinician organizations##
Flowchart to Identify and Assess 2019 Novel Coronavirus

For the evaluation of patients who may be ill with or who may have been exposed to 2019 Novel Coronavirus (2019-nCoV)

A. Identify if in the past 14 days since first onset of symptoms a history of either
   - Travel to China
   - OR
   - Close contact with a person known to have 2019-nCoV illness*

B. AND the person has
   - Fever or symptoms of lower respiratory illness
     (e.g., cough or shortness of breath)
     *if both exposure and illness are present*

1. Isolate
   - Place facemask on patient
   - Isolate the patient in a private room or a separate area
   - Wear appropriate personal protective equipment (PPE)

2. Assess clinical status
   - EXAM
   - Is fever present?
     - Subjective?
     - Measured? _____°C/F
   - Is respiratory illness present?
     - Cough?
     - Shortness of breath?

3. Inform
   - Contact health department to report at-risk patients and their clinical status
   - Assess need to collect specimens to test for 2019-nCoV
   - Decide disposition

   If discharged to home

   Instruct patient
   - As needed depending on severity of illness and health department consultation
     - Home care guidance
     - Home isolation guidance

   Advise patient
   - If the patient develops new or worsening fever or respiratory illness
     - Call clinic to determine if reevaluation is needed
     - If reevaluation is needed call ahead and wear facemask

* Documentation of laboratory-confirmation of 2019-nCoV may not be possible for travelers or persons caring for patients in other countries. For more clarification on the definition for close contact see CDC’s Interim Guidance for Healthcare Professionals: www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html